Dhimant Patel

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight‐based dose using a front‐loading schedule in patients with anemia who have nonmyeloid malignancies

Paul J. Hesketh, Francis P. Arena, Dhimant Patel et al. · Cancer · 2004 · 53 citations · Full text

Medicine, Hematology, Pharmacology +17

Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study

Kari B. Wisinski, Wei Xu, Amyé Tevaarwerk et al. · Clinical Breast Cancer · 2016 · 46 citations

Medicine, Endocrinology, Oncology +17